HK Stock Market Move | XUANZHUBIO-B (02575) surged over 5% in the morning session, with mid-term revenue increasing by 288.1% year-on-year, driven by dual efforts in external authorizations and licensing introductions.

XUANZHUBIO-B (02575) surged over 5% in the morning and as of the time of writing, it has risen by 5.42%, trading at HK$9.915, with a transaction volume of HK$2.7797 million. In news, XUANZHUBIO-B announced its results for the six months ending June 30, 2026, reporting a revenue of RMB 69.4 million, an increase of 288.1% year-on-year. The announcement stated that the revenue growth was mainly driven by sales increases from new product launches and being included in the national basic medical insurance drug list. During the reporting period, the group advanced its overall business steadily along four main lines: commercialization, clinical development, early-stage R&D, and business development (BD). On the commercialization front, the distribution network and academic recognition of the three products already on the market continued to improve. In terms of clinical development, several key studies of the core products achieved important milestones. On the early-stage R&D side, the technical platform capabilities continued to expand, with multiple new projects completed and initiated. Regarding BD, the company made progress in both outbound licensing and inbound permissions, achieving substantial breakthroughs in its global layout.